C&G Editor in Chief, Erin Harris
-
Is A One-Time Cure for HIV on the Horizon?
5/14/2024
Addimmune's CMO, Dr. Marcus Conant, shares information about the company's lead asset, AGT103-T, which has been designed to provide a functional cure for HIV.
-
Cell & Gene: The Podcast Post-Episode Recap: BlueRock Therapeutics’ Dr. Ahmed Enayetallah
4/30/2024
This article shares highlights from Cell & Gene: The Podcast featuring BlueRock Therapeutics’ Dr. Ahmed Enayetallah. Heshares impressive data from the Phase 1 study to treat Parkinson's disease.
-
Cell & Gene: The Podcast Post-Episode Recap: Vor Bio’s Dr. Robert Ang
4/26/2024
Welcome to my new article series, Cell & Gene: The Podcast Post-Episode Recap, which shares highlights, quotes, and more from recently aired episodes of Cell & Gene: The Podcast.
-
2024: The Year of Development in Cell Therapy
4/10/2024
We break down three trends driving development in cell therapy in 2024.
-
Nanoscope Therapeutics Tackling Vision Loss With Ocular Gene Therapy
3/27/2024
Leaders from Nanoscope Therapeutics explain the safety and efficacy data from as well as next steps for the company's RESTORE trial.
-
ICYMI: Q1 2024’s Cell & Gene Live And Cell & Gene: The Podcast
3/27/2024
With Q1 of 2024 coming to close, I wanted to take this opportunity to make sure you’ve read, heard, or viewed some of insightful content we’ve created for Cell & Gene's readers since the start of the year.
-
Inside Tenaya Therapeutics’ AAV9-Based Gene Therapy
3/27/2024
Tenaya Therapeutics' CSO explains how the company's gene therapy, TN-401, may treat heart disease.
-
Rare Disease Day 2024
2/29/2024
Today is Rare Disease Day 2024, a global initiative to raise awareness and generate support for everyone who is on a rare medical journey.
-
Video Clips From Cell & Gene Live: 2024 Regulatory Outlook With FDA's Dr. Peter Marks And Dr. Nicole Verdun
2/27/2024
Our recent Cell & Gene Live, 2024 Regulatory Outlook With FDA's Drs. Peter Marks and Nicole Verdun, was a chock full of data and valuable information. I've broken down the full-length presentation into bite sized video clips that you can view at your convenience.
-
Inside Cell & Gene Live “How To Reduce Batch-To-Batch Variation In Cell Therapy Manufacturing”
2/26/2024
Here's a recap of our recent Cell & Gene Live, How to Reduce Batch-to-Batch Variation in Cell Therapy Manufacturing, featuring expert panelists, Omkar Kawalekar, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte and Donna Rill, Chief Technology Officer at Triumvira Immunologics.